Factors influencing the short-term and long-term survival of hepatocellular carcinoma patients with portal vein tumor thrombosis who underwent chemoembolization

Table 1 Characteristic of the 181 patients

Parameters	Patients, n = 181
Age in yr	52.16 ± 9.73
Sex, men/women	159/22
Cause of liver disease, hepatitis B/C/B and C/others	163/3/1/14
Tumor size, < 5 cm/≥ 5 cm, < 10 cm/≥ 10 cm	39/86/56
Number of tumors, 1/2/≥ 3	82/12/87
Liver cirrhosis, no/yes	48/133
Ascites, no/small/moderate-massive	91/70/20
CTPV, no/yes	158/23
Invade left and right liver lobes, no/yes	119/62
Type of gross pathology, massive/nodular/diffuse	112/59/10
PVTT type, I/II/III/IV	29/77/68/7
Inferior vena cava tumor thrombus, no/yes	171/10
Arteriovenous fistula, no/yes	125/56
Total bilirubin, µmol/L	17.1 (12.3-24.7)
Prealbumin, mg/L	110 (79-147)
Albumin, g/L	37 ± 4.8
Hemoglobin, g/L	127 (115-142)
WBC, 109/L	5.1 (3.925-6.505)
PLT, 109/L	116 (81- 179.5)
INR	1.12 (1.055-1.205)
PT, S	14.3 (13.7-15.25)
APTT, S	39.5 (37-42.8)
ALT, U/L	46 (31-71.5)
AST, U/L	65 (46-109.5)
GGT, U/L	211 (124.5-352.5)
Cholinesterase, kU/L	4.5 (3.065-5.78)
Creatinine, µmol/L	68 (57.7-78.1)
AFP, µg/L	1210 (82.905-1210)
Child-Pugh grade, A/B/C	123/55/3
ECOG score, 0/1/2/3	8/142/29/2
ALBI grade, 1/2/3	56/120/5
MELD score	7.67 (6.08-9.54)
Overall survival time, mo	4.8 (2.5-8.85)

AFP: Alpha fetoprotein; ALBI: Albumin-bilirubin; ALT: Alanine aminotransferase; APTT: Activated partial thromboplastin time; AST: Aspartate aminotransferase; CTPV: Cavernous transformation of the portal vein; ECOG: Eastern Cooperative Oncology Group; GGT: Gamma-glutamyl transpeptidase; INR: International normalized ratio; MELD: Model of end-stage liver disease; PLT: Platelets; PVTT: Portal vein tumor thrombosis; WBC: White blood cell.